News | May 28, 2025
Sanjivani Paranteral posts Q4 FY25 at Rs. 2.19 Cr
For FY25, Revenue from operation grew 28.8 per cent YoY to Rs. 70.1 crore
For FY25, Revenue from operation grew 28.8 per cent YoY to Rs. 70.1 crore
The CDMO upgrade represents a transformational step for Remedium Lifecare
EBITDA before special items decreases to €4.08 billion (7.4%)
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
he inspection covering the sterile drug product filling and packaging line, quality systems and quality control laboratories concluded compliance with the principles and guidelines of Good Manufacturing Practice
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Bayer expects 2025 to be the most difficult year of its turnaround
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
Subscribe To Our Newsletter & Stay Updated
